Dr. Cosgrove is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
210 SE 136th Ave
Vancouver, WA 98684Phone+1 360-944-9889Fax+1 360-944-9686
Summary
- Dr. Cosgrove specializes in general adult oncology with advanced subspecialty expertise in breast and gastrointestinal (GI) cancers. He is a strong advocate for bringing leading edge therapies to his patients through clinical trials. He serves on The US Oncology Research Network’s national GI Research Committee and as a principal investigator for many studies.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009- Johns Hopkins UniversityResidency, Internal Medicine, 2003 - 2006
University College of Dublin National Univ SOMClass of 2000
Certifications & Licensure
OR State Medical License 2015 - 2025
WA State Medical License 2015 - 2025
MD State Medical License 2006 - 2016
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
- QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Start of enrollment: 2012 Jan 01
- Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy Start of enrollment: 2011 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC.Nilofer Azad, Zishuo Hu, Ilyas Sahin, Renuka Iyer, Olivia Aranha
Future Oncology. 2024-01-01 - 28 citationsRegorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase ...Marwan Fakih, Kanwal Pratap Singh Raghav, David Z Chang, Tim Larson, Allen L Cohn
Eclinicalmedicine. 2023-04-01 - 2 citationsReal-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.David P Cosgrove, Emily S Reese, Nicole M Fulcher, Sarah S Bobiak, Francois-Xavier Lamy
Cancer Medicine. 2023-02-01
Other Languages
- German
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/david-cosgrove
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
